<div><div></div><div>Aligos reported $2.186 million in revenue for the year and a net loss per share of $(2.45), with revenue down 39% versus the prior year largely due to the end of a collaboration portion with Amoytop and subsequent changes following a Merck agreement. The company posted a net loss of $(24.193) million (an 82% improvement year-over-year) and a loss from operations of $(87.985) million; a $60.184 million unrealized gain from revaluation of 2023 common warrants materially reduced pre-tax loss. Cash is expected to fund operations into Q3 2026, creating near-term financing needs to sustain R&amp;D programs. Financial Highlights <ul><li>Revenue from customers: $2.186 million, down 39% versus prior year.</li><li>Operating income (loss): Loss from operations of $(87.985) million.</li><li>Net income (net loss): Net loss of $(24.193) million, improved 82% versus prior year.</li><li>Net income per share: Net loss per share, basic and diluted: $(2.45).</li><li>Change in fair value of 2023 Common Warrants: $60.184 million gain that materially improved pre-tax loss.</li></ul> Business Highlights <ul><li>Pipeline progress: Advanced pevifoscorvir sodium through 96-week Phase 1 and initiated the Phase 2 B-SUPREME study, with interim analyses planned in 2026.</li><li>Clinical milestones: ALG-055009 met the Phase 2a MRI-PDFF primary endpoint with significant liver fat reductions; preclinical data showed potential weight-loss synergy in combination studies.</li><li>Revenue mix shift: Customer collaboration revenue fell roughly 39% in 2025 after the Amoytop collaboration portion ended; collaboration revenue ceased following the Merck agreement.</li><li>Operational funding &amp; grants: Received approximately $15.3 million in NIH/NIAID funding for coronavirus programs and is seeking external or public funding to support development of ALG-097558.</li><li>Liquidity and runway: Cash is expected to fund operations into Q3 2026; the company will need to secure additional capital to avoid curtailing R&amp;D activities.</li></ul>Original SEC Filing: Aligos Therapeutics, Inc. [ ALGS ] - 10-K - Mar. 05, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

ARKG

Aligos reported $2.186 million in revenue for 2025, a 39% decrease from the previous year, primarily due to the end of a collaboration with Amoytop and changes following a Merck agreement. The net loss improved to $(24.193) million, with a loss per share of $(2.45). A $60.184 million unrealized gain from common warrants helped reduce pre-tax losses. The company expects cash to fund operations into Q3 2026 but will need additional capital to sustain R&D programs. Key pipeline advancements include progress in clinical studies for pevifoscorvir sodium and ALG-055009.

TradingView

VG Health

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

iShares Biotechnology ETF

iShares Global Healthcare

Merck

First Trust NYSE Arca Biotech Index Fd

AMOYTOP

Aligos Therapeutics

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing